BOSTON ( TheStreet) -- Welcome to October's Biotech Stock Mailbag Live Chat. The floor is yours.

I'm here for the next 90 minutes to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing in the box below.

Biotech earnings season kicks off in earnest next week, with reports due from Celgene ( CELG), Biogen Idec ( BIIB), Amgen ( AMGN) and Gilead Sciences ( GILD).

Investors will be paying close attention to Vertex Pharmaceuticals ( VRTX) when it reports Incivek sales on Oct. 27.

Human Genome Sciences ( HGSI) will be reporting third-quarter Benlysta sales amidst investor concerns about the lupus drug's slow launch. And what about those rumors of a GlaxoSmithkline ( GSK) takeout? Optimer Pharmaceuticals ( OPTR) appears to be bucking the "slow launch" trend with its antibiotic Dificid.

Let's discuss FDA drug approvals: Onyx Pharmaceuticals ( ONXX), Neoprobe ( NEOP), Incyte ( INCY), Alexza Pharmaceuticals ( ALXA) and MAP Pharma ( MAPP), among others.

I've raised a ruckus with Keryx Pharma ( KERX) predicting the failure of the colon cancer drug perifosine, but I'm more than happy to continue the debate today.

Let's talk about these stocks today, or any other biotech investing subjects that pique your interest. Please join me live.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Apple Is the Tom Brady of Stocks: Cramer's 'Mad Money' Recap (Thursday 8/31/17)

Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks